It is not intended for human or veterinary use
ASA News Release
The lawsuit claims that the two companies, Novo Nordisk and Eli Lilly, knew of the association between the use of GLP-1 receptor agonists and the risk of developing severe gastrointestinal issues, including gastroparesis and gastroenteritis. Their failure to disclose information that they possessed regarding the association between the use of GLP-1 receptor agonists and the risk of developing severe gastrointestinal issues, including gastroparesis and gastroenteritis, rendered the warnings for this medication inadequate, it continues
Recent investments in building and expanding manufacturing capacity have helped grow supply, Novo said
These findings are derived from controlled research environments and are intended solely to advance scientific understanding of cellular aging mechanisms and peptideDNA interactions
These effects were more prominent in rats, more robust after bolus injection, and attenuated after repeated dosing
